IPM Take
This is not a clean “new drug wins” story. That is exactly why it is useful. Oral SERDs may become important in ER-positive, HER2-negative breast cancer, but ASCO 2026 shows the placement question is unresolved. Giredestrant has positive data in some settings and a negative primary endpoint in another. The policy lesson is simple: precision oncology needs evidence discipline. A promising class still has to prove where it belongs.
Executive Summary
Roche presented multiple giredestrant datasets at ASCO 2026. These included lidERA subgroup data in ER-positive, HER2-negative early breast cancer and the primary analysis of persevERA in first-line locally advanced or metastatic ER-positive, HER2-negative breast cancer. Roche stated before ASCO that persevERA did not meet its primary endpoint, although the combination showed a numerical PFS improvement. The ASCO abstract for persevERA presents the primary analysis, while another ASCO abstract reports lidERA efficacy and safety by menopausal subgroup.
Why it matters
- Clinicians: Need clarity on whether oral SERDs belong in early disease, after CDK4/6 progression, first-line metastatic disease or selected biomarker-defined settings.
- HTA bodies / payers: Mixed evidence across settings makes value assessment more complex.
- Patients / advocates: Oral treatment is attractive, but access should follow evidence, not class enthusiasm.
The breast cancer field is not short of endocrine therapy. The question is whether oral SERDs can do something meaningfully better.
That answer is becoming more nuanced. In early ER-positive, HER2-negative breast cancer, giredestrant has generated positive signals. In first-line advanced disease with palbociclib, persevERA did not meet its primary endpoint. That does not erase the programme, but it changes the editorial framing. This is not a story of simple success. It is a story of fit.
Where a drug works can matter as much as whether it works. Earlier disease, resistant disease, ESR1-mutant disease, post-CDK4/6 disease and first-line endocrine-sensitive disease are not interchangeable settings. Treating them as one market or one pathway risks poor clinical and reimbursement decisions.
For IPM, the access issue is evidence positioning. Oral SERDs may become part of future breast cancer care, but systems need to know which patients benefit, when the switch should happen and how endocrine therapy should be sequenced alongside CDK4/6 inhibitors, targeted therapies and ADCs.
